Familial Chylomicronemia Syndrome (FCS / LPLD / Type 1 Hyperlipoproteinemia)

What changes during this transition

Familial Chylomicronemia Syndrome (FCS) — also LPLD (lipoprotein lipase deficiency) or type 1 hyperlipoproteinemia — is an ultra-rare autosomal recessive disorder of triglyceride metabolism, caused by biallelic loss-of-function mutations in LPL (most common — the lipoprotein lipase enzyme itself) or in its cofactors APOC2, APOA5, GPIHBP1, or LMF1. The shared mechanism is impaired clearance of triglyceride-rich chylomicrons from circulation, producing severe persistent hypertriglyceridemia (>880 mg/dL diagnostic, often >2000 mg/dL in poorly controlled disease) and a fasting plasma that is visibly lactescent ('milky'). The cardinal complication, and the #1 cause of mortality and chronic morbidity across the FCS lifespan, is RECURRENT ACUTE PANCREATITIS. Patients typically present in childhood with their first pancreatitis episode, accumulate repeated attacks across the lifespan, and progressively destroy exocrine and endocrine pancreatic tissue with consequences including exocrine pancreatic insufficiency, fat-soluble vitamin malabsorption, and type 3c pancreatogenic diabetes. The disease was historically managed with the extreme fat-restricted diet alone — <10-15% calories from fat, sometimes <20g/day, with medium-chain triglycerides used for caloric density because MCTs are absorbed via the portal vein bypassing the chylomicron pathway entirely. This dietary regimen is quality-of-life-defining and lifelong. The therapeutic landscape was transformed by APOC3 antisense oligonucleotide therapy: VOLANESORSEN (Waylivra, Akcea/Ionis) was EMA-approved in May 2019 — the first disease-modifying therapy for FCS, a multi-jurisdictional reality per Rule 11 where European regulatory approval preceded US action; the Phase 3 APPROACH and COMPASS trials demonstrated substantial triglyceride lowering, but the FDA review path was complicated by a thrombocytopenia signal, and volanesorsen was not FDA-approved (it remains accessible through European supply paths with mandatory platelet surveillance); SC weekly. OLEZARSEN (Tryngolza, Ionis) is a newer GalNAc-conjugated APOC3 antisense oligonucleotide FDA-approved in December 2024 for FCS — the first FDA-approved FCS therapy and a paradigm shift after decades of dietary-management-only standard-of-care in the US; the GalNAc structure improves hepatocyte targeting and reduces the thrombocytopenia signal that limited volanesorsen's FDA path; SC monthly. Both agents work by reducing apoC-III levels, which enhances LPL-independent triglyceride clearance — addressing the monogenic chylomicron-clearance defect through a parallel pathway. Standard statins and fibrates are ineffective for monogenic FCS. Plasmapheresis for acute hypertriglyceridemic pancreatitis. FCS Foundation (fcsfoundation.org) is the principal US patient advocacy organization; ACTION FCS registry is the international natural-history registry; IDEAL FCS represents the multi-jurisdictional clinical study program. Pediatric onset typically — families navigating life-threatening recurrent pancreatitis in children, with the editorial sensitivity that the desperation of pediatric rare-disease families is a known vector for community peptide market exploitation. No peptide in the Juno library has a discovery-card-defensible FCS case. BPC-157 is one of the sharpest mechanism-vs-disease contradictions in the substrate — the 'gut healing' community framing collides directly with FCS recurrent pancreatitis (where recurrent inflammation of an abdominal organ IS the disease). NMN reaches the population through the general-aging channel in the aging-FCS demographic from the APOC3-ASO era. The GH-axis trio (CJC-1295 + ipamorelin + tesamorelin) overlaps with pediatric-FCS growth questions where disease control is the lever, with tesamorelin Rule 6 non-propagation sharpest in the trio. Semaglutide is the SHARPEST coordination-of-care conversation in the semaglutide substrate — GLP-1 agonists carry a pancreatitis warning on the FDA label across the class, and FCS patients have baseline pancreatitis risk from chylomicron-driven recurrent acute pancreatitis that IS the disease; this is not a routine obesity-medicine conversation but a multi-specialist triangulation. Eighty-seventh deliberate non-elevation.